Johnson & Johnson's (JNJ -1.58%) med device segment had a pretty sleepy first quarter, with 0.7% revenue growth (about 1% operationally). But management highlighted some new and exciting opportunities for this underloved division, including a huge potential tailwind from the Affordable Care Act (also known as Obamacare). Watch the video below for more on this exciting growth opportunity.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.